127 related articles for article (PubMed ID: 36946610)
21. Multi-institutional Phase II study of proton beam therapy for organ-confined prostate cancer focusing on the incidence of late rectal toxicities.
Nihei K; Ogino T; Onozawa M; Murayama S; Fuji H; Murakami M; Hishikawa Y
Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):390-6. PubMed ID: 20832180
[TBL] [Abstract][Full Text] [Related]
22. Long-Term Outcomes of Dose-Escalated Pelvic Lymph Node Intensity-Modulated Radiation Therapy (IMRT) With a Simultaneous Hypofractionated Boost to the Prostate for Very High-Risk Adenocarcinoma of the Prostate: A Prospective Phase II Clinical Trial.
Hall WA; Bedi M; Kilari D; Bylow KA; Burfeind J; Johnstone C; Siker M; Currey A; See WA; Nelson A; Johnson S; Straza M; Lawton CAF
Pract Radiat Oncol; 2021; 11(6):527-533. PubMed ID: 33848618
[TBL] [Abstract][Full Text] [Related]
23. Does Race Influence Health-related Quality of Life and Toxicity Following Proton Therapy for Prostate Cancer?
Bryant C; Mendenhall NP; Henderson RH; Nichols RC; Mendenhall WM; Morris CG; Williams C; Su Z; Li Z; Hoppe BS
Am J Clin Oncol; 2016 Jun; 39(3):261-5. PubMed ID: 24710124
[TBL] [Abstract][Full Text] [Related]
24. Prognostic factors, efficacy, and toxicity of involved-node stereotactic body radiation therapy for lymph node oligorecurrent prostate cancer : An investigation of 117 pelvic lymph nodes.
Cozzi S; Botti A; Timon G; Blandino G; Najafi M; Manicone M; Bardoscia L; Ruggieri MP; Ciammella P; Iotti C
Strahlenther Onkol; 2022 Aug; 198(8):700-709. PubMed ID: 34757443
[TBL] [Abstract][Full Text] [Related]
25. Phase II study of long-term androgen suppression with bevacizumab and intensity-modulated radiation therapy (IMRT) in high-risk prostate cancer.
Vuky J; Pham HT; Warren S; Douglass E; Badiozamani K; Madsen B; Hsi A; Song G
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):e609-15. PubMed ID: 22208976
[TBL] [Abstract][Full Text] [Related]
26. Salvage of locally recurrent prostate cancer after external beam radiation using reduced-dose brachytherapy with neoadjuvant plus adjuvant androgen deprivation.
Baumann BC; Baumann JC; Christodouleas JP; Soffen E
Brachytherapy; 2017; 16(2):291-298. PubMed ID: 28139422
[TBL] [Abstract][Full Text] [Related]
27. Outcomes and prognostic factors in intermediate-risk prostate cancer: multi-institutional analysis of the Spanish RECAP database.
Hervás A; Pastor J; González C; Jové J; Gómez A; Casaña M; Villafranca E; Mengual JL; Muñoz V; Henriquez I; Muñoz J; Collado E; Clemente J
Clin Transl Oncol; 2019 Jul; 21(7):900-909. PubMed ID: 30536208
[TBL] [Abstract][Full Text] [Related]
28. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.
Duchesne GM; Woo HH; Bassett JK; Bowe SJ; D'Este C; Frydenberg M; King M; Ledwich L; Loblaw A; Malone S; Millar J; Milne R; Smith RG; Spry N; Stockler M; Syme RA; Tai KH; Turner S
Lancet Oncol; 2016 Jun; 17(6):727-737. PubMed ID: 27155740
[TBL] [Abstract][Full Text] [Related]
29. Prostate cancer patient subsets showing improved bNED control with adjuvant androgen deprivation.
Anderson PR; Hanlon AL; Movsas B; Hanks GE
Int J Radiat Oncol Biol Phys; 1997 Dec; 39(5):1025-30. PubMed ID: 9392540
[TBL] [Abstract][Full Text] [Related]
30. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
[TBL] [Abstract][Full Text] [Related]
31. Stage T1c prostate cancer: a heterogeneous category with widely varying prognosis.
Hung AY; Levy L; Kuban DA
Cancer J; 2002; 8(6):440-4. PubMed ID: 12500852
[TBL] [Abstract][Full Text] [Related]
32. Anterior-oriented proton beams for prostate cancer: A multi-institutional experience.
Cuaron JJ; Harris AA; Chon B; Tsai H; Larson G; Hartsell WF; Hug E; Cahlon O
Acta Oncol; 2015 Jun; 54(6):868-74. PubMed ID: 25591937
[TBL] [Abstract][Full Text] [Related]
33. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
[TBL] [Abstract][Full Text] [Related]
34. Long-term results of a prospective, Phase II study of long-term androgen ablation, pelvic radiotherapy, brachytherapy boost, and adjuvant docetaxel in patients with high-risk prostate cancer.
Dibiase SJ; Hussain A; Kataria R; Amin P; Bassi S; Dawson N; Kwok Y
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):732-6. PubMed ID: 21036486
[TBL] [Abstract][Full Text] [Related]
35. High-dose-rate brachytherapy monotherapy without androgen deprivation therapy for intermediate-risk prostate cancer.
Patel S; Demanes DJ; Ragab O; Zhang M; Veruttipong D; Nguyen K; Park SJ; Marks L; Pantuck A; Steinberg M; Kamrava M
Brachytherapy; 2017; 16(2):299-305. PubMed ID: 27965117
[TBL] [Abstract][Full Text] [Related]
36. Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy.
Pervez N; Small C; MacKenzie M; Yee D; Parliament M; Ghosh S; Mihai A; Amanie J; Murtha A; Field C; Murray D; Fallone G; Pearcey R
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):57-64. PubMed ID: 19395192
[TBL] [Abstract][Full Text] [Related]
37. Acute genitourinary toxicity of pencil beam scanning proton therapy for localized prostate cancer: utility of the transition zone index and average urinary flow rate in predicting acute urinary retention.
Takaoka T; Yanagi T; Tanaka A; Kiriyama Y; Tanaka Y; Kondo T; Takano S; Takahashi S; Shibamoto Y; Tomita N; Hiwatashi A
Jpn J Clin Oncol; 2023 Apr; 53(5):419-428. PubMed ID: 36722357
[TBL] [Abstract][Full Text] [Related]
38. Proton Therapy for Localized Prostate Cancer: Long-Term Results From a Single-Center Experience.
Takagi M; Demizu Y; Fujii O; Terashima K; Niwa Y; Daimon T; Tokumaru S; Fuwa N; Hareyama M; Okimoto T
Int J Radiat Oncol Biol Phys; 2021 Mar; 109(4):964-974. PubMed ID: 33186616
[TBL] [Abstract][Full Text] [Related]
39. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
[TBL] [Abstract][Full Text] [Related]
40. Hypofractionated accelerated radiotherapy using concomitant intensity-modulated radiotherapy boost technique for localized high-risk prostate cancer: acute toxicity results.
Lim TS; Cheung PC; Loblaw DA; Morton G; Sixel KE; Pang G; Basran P; Zhang L; Tirona R; Szumacher E; Danjoux C; Choo R; Thomas G
Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):85-92. PubMed ID: 18355982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
